Actively Recruiting
Phase II Study of SHR-1826 Injection with Other Drugs for Treating Advanced or Metastatic NSCLC
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-03-19
300
Participants Needed
1
Research Sites
78 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are conducting a Phase II, open-label, multicenter clinical trial to study SHR-1826 for injection in patients with non-small cell lung cancer NSCLC. The trial aims to evaluate the safety, tolerability, and effectiveness of SHR-1826 when used in combination with other drugs in patients with locally advanced or metastatic NSCLC. The study is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. Participants will receive SHR-1826 through intravenous infusion every 3 weeks combined with Adebrelimab every 3 weeks and SHR-8068 every 6 weeks. Some patients may also receive Bevacizumab every 3 weeks as part of the treatment regimen. This study involves one experimental treatment arm with these drug combinations. During the study, participants will be monitored for about 2 years to assess the incidence and severity of adverse events and the overall response rate to treatment. Other outcomes tracked include duration of response, disease control rate, progression-free survival, and overall survival up to 5 years after the last participant is enrolled. Participants will undergo tumor assessments, organ function tests, and tumor tissue analysis as part of their involvement.
CONDITIONS
Brief Title
A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC
Research Team
L
Li Song
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
